Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications
Ersodetug for Refractory Hypoglycemia Due to Malignant Insulin-Secreting Tumors.
Journal: The Journal of clinical endocrinology and metabolism
Published: May 26, 2026
Global, multi-center, repeat-dose, phase 2 study of RZ358 (ersodetug), an insulin receptor antibody, for congenital hyperinsulinism.
Journal: Med (New York, N.Y.)
Published: October 09, 2024
The Birth Prevalence of Congenital Hyperinsulinism: A Narrative Review of the Epidemiology of a Rare Disease.
Journal: Hormone research in paediatrics
Published: April 19, 2024
Showing 1-3 of 3
Last Updated: 09/26/2026